Eledon Pharmaceuticals Inc Ordinary Shares ELDN 深 沪
已收盘 09-12 16:00:00 美东时间
2.42
-0.120
-4.72%
华盛通- 最 高2.545
- 今 开2.52
- 成交量 67.76万股
- 最 低 2.41
- 昨 收 2.54
- 总市值 1.45亿
- 52周最高 5.54
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.375
- 委 比 49.46%
- 总股本 5988.18万
- 历史最高 154.98
- 量 比 0.95
- 振 幅 5.31%
- 历史最低 1.07
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Reiterates Buy on Eledon Pharmaceuticals, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and maintains $9 price target.
09-02 19:05
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025. The event will be webcast and available for replay on the company's website. Eledon is a biotech company developing immune-modulating therapies, with its lead product, tegoprubart, targeting CD40L for conditions like kidney transplantation and ALS.
08-29 11:00
Eledon Pharmaceuticals Advances in Transplant Trials
Eledon Pharmaceuticals, Inc. ( ($ELDN) ) has released its Q2 earnings. Here is ...
08-19 12:14
Eledon Pharma Q2 EPS $(0.13) Beats $(0.24) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.24) by 46.72 percent. This is a 85.87 percent increase over losses of $(0.92) per share from the
08-15 04:45
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
Eledon Pharmaceuticals reported its 2Q25 financial results and highlighted business progress, including positive data on its immunosuppressive drug tegoprubart in kidney transplantation, which showed stable kidney function with minimal side effects. The company achieved key milestones in kidney, islet cell, and liver allotransplantation, as well as xenotransplantation. Cash reserves stood at $107.6 million as of June 30, 2025, and R&D expenses ro...
08-14 20:20
Voyager Eledon Presents Data From Phase 1b Trial Evaluating Tegoprubart for Prevention Of Rejection In Kidney Transplant Patients
Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplantPreliminary iBox data, a key biomarker of kidney function and immunologic
08-07 04:54
美股大行评级 | 潜在涨幅102.43%！Mobileye Global获Canaccord Genuity升目标价至30美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Mobileye Global"买入"评级，目标价从25美元升至30美元；巴克莱：维持TechnipFMC"超配"评级，目标价从45美元升至51美元
07-28 09:33
Craig-Hallum Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Craig-Hallum initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-26 01:54
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
Eledon Pharmaceuticals will present updated clinical data on tegoprubart for kidney transplantation at the World Transplant Congress in San Francisco on August 6, 2025. The presentation by Dr. John Gill from the University of British Columbia will include results from approximately 30 kidney transplant recipients. Additionally, preclinical data on tegoprubart for liver transplantation in non-human primates will be presented in a poster session. E...
07-17 20:01
Eledon And Sernova Collaborate To Test Tegoprubart As Safer Immunosuppressant In Sernova's Phase 1/2 Cell Pouch Trial For Type 1 Diabetes
Sernova Biotherapeutics ("Sernova") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) to evaluate Eledon's
07-09 20:36
